A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period

Trial Profile

A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TERICIS
  • Most Recent Events

    • 16 Mar 2018 Planned End Date changed from 1 Oct 2018 to 18 Jan 2019.
    • 16 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 18 Jan 2019.
    • 16 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top